Skip to Main Content

Advertisement

Skip Nav Destination

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Blood (2019) 134 (13): 1024–1036.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement